Please login to the form below

Not currently logged in
Email:
Password:

Citryll snares €15m backing for its autoimmune disease NETs

New approach to tackling diseases such as lupus, RA

Cit2

Dutch biotech Citryll has raised €15m ($17m) in first-round financing to help advance its new therapeutic approach to autoimmune diseases.

The company – which span out of contract research and laboratory tool company ModiQuest in 2015 – is developing a platform based on antibodies that prevent the formation of neutrophil extracellular traps (NETs), though to play a key role in autoimmunity.

NETs are networks of extracellular fibres, primarily composed of DNA from neutrophils, which bind to invading pathogens and are a part of the body’s immune defence that doesn’t involve damage to host cells.

In some autoimmune disease such as lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis, it is thought that NETs inadvertently react to host cells, stimulating the release of autoantigens – particularly citrullinated proteins – as well as inflammatory proteins and other toxic compounds.

The new funding will go towards the continued development of Citryll’s lead programme tACPA, which is designed to interfere with the production of NETs, a process catalysed by the peptidylarginine deiminase (PAD) enzyme pathway. tACPA binds citrullinated histones that are believed to be essential for NET formation.

Other companies including Bristol-Myers Squibb (via its $600m acquisition of Padlock Therapeutics in 2016) are working on small-molecule PAD inhibitors for autoimmune disease. Citryll thinks however that its approach – which works downstream of PAD - will be more specific to disease-associated NETs and won’t involve blockade of normal PAD functions that could lead to side effects.

Helmuth

Helmuth van Es

Citryll’s chief executive Helmuth van Es believes that drugs that interfere with NETs and their production “have the potential to create game changing new treatments to prevent or treat human diseases.”

He explains: “Citryll’s approach does not broadly target inflammation or acquired immunity, instead it extinguishes the source of autoantigens and (NET)-derived toxic molecules in the safest way currently possible.”

The €15m in Series A funding, backed by ModiQuest, BOM Brabant Ventures, BrightGene, and Curie Capital, will be used to progress Citryll’s tACPA antibodies through preclinical and clinical development.

Article by
Phil Taylor

5th July 2019

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics